Table 2.
Univariate analysis of transplant outcomes according to donor type
| Outcomea | MSD | MUD | Haplo | p |
|---|---|---|---|---|
| Acute GvHD, % (95% CI) | ||||
| Grade II–IV | 34 (23–45) | 41 (30–51) | 32 (27–38) | 0.4 |
| Grade III–IV | 15 (8–24) | 15 (9–24) | 13 (9–17) | 0.8 |
| Chronic GvHD, % (95% CI) | ||||
| Overall | 42 (29–54) | 50 (37–61) | 35 (29–41) | 0.01 |
| Extensive | 21 (12–33) | 17 (9–27) | 11 (7–15) | 0.2 |
| NRM, % (95% CI) | 21 (12–32) | 18 (10–27) | 21 (17–26) | 0.8 |
| RI, % (95% CI) | 28 (17–41) | 20 (12–30) | 20 (16–26) | 0.8 |
| LFS, % (95% CI) | 51 (37–63) | 62 (50–72) | 59 (52–64) | 0.8 |
| OS, % (95% CI) | 62 (48–73) | 69 (57–79) | 66 (60–72) | 0.8 |
| GRFS, % (95% CI) | 35 (23–47) | 44 (32–55) | 46 (40–52) | 0.9 |
GvHD, graft-versus-host disease; CI, confidence interval; p, p value; NRM, non-relapse mortality; RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; GRFS, graft-versus-host disease-free, relapse-free survival; MSD, matched sibling donor; MUD, matched unrelated donor; Haplo, haploidentical donor
aAcute GvHD: 100-day cumulative incidence; cGvHD, NRM and RI: cumulative incidence at 2 years; DFS, OS and GRFS: survival probability at 2 years